Changing the name of diabetes insipidus: a position statement of the working group to consider renaming diabetes insipidus

AUTOR(ES)

Arima, Hiroshi; Cheetham, Timothy; Christ-Crain, Mirjam; Cooper, Deborah L.; Drummond, Juliana B.; Gurnell, Mark; Levy, Miles; McCormack, Ann; Newell-Price, John D.; Verbalis, Joseph G.; Wass, John

FONTE

Archives of Endocrinology and Metabolism

DATA DE PUBLICAÇÃO

2022

RESUMO

“What's in a name? That which we call a rose / By any other name would smell as sweet” (Juliet, from Romeo and Juliet by William Shakespeare). Shakespeare's implication is that a name is nothing but a word and it therefore represents a convention with no intrinsic meaning. Whilst this may be relevant to romantic literature, disease names do have real meanings, and consequences, in medicine. Hence, there must be a very good rational for changing the name of a disease that has a centuries-old historical context. A working group of representatives from national and international endocrinology and endocrine pediatric societies now proposes changing the name of “diabetes insipidus” to “Arginine Vasopressin Deficiency (AVP-D)” for central etiologies, and “Arginine Vasopressin Resistance (AVP-R)” for nephrogenic etiologies This editorial provides both the historical context and the rational for this proposed name change.

Documentos Relacionados

• Idiopathic central diabetes insipidus: the challenge remains
• Central diabetes insipidus: a complication of herpes simplex encephalitis.
• Lithium-induced nephrogenic diabetes insipidus: in vivo and in vitro studies
• Nephrogenic diabetes insipidus: an X chromosome-linked dominant inheritance pattern with a vasopressin type 2 receptor gene that is structurally normal.
• Sequestration of urea and nonurea solutes in renal tissues of rats with hereditary hypothalamic diabetes insipidus: effect of vasopressin and dehydration on the countercurrent mechanism.